Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
February 24 2021 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will participate at
the following conferences:
Cowen 41st Annual Health Care Conference Date: Monday,
March 1, 2021 Analyst-hosted fireside chat: 12:30 PM ET
Raymond James 42nd Annual Institutional Investors
Conference Date: Wednesday, March 3, 2021 Analyst-hosted
fireside chat: 9:10 AM ET
H.C. Wainwright Global Life Sciences Conference Date:
March 9-10, 2021 Pre-Recorded Formal Presentation will be made
available on Tuesday, March 9, 2021 at 7:00 AM ET
Management will be available throughout the day for virtual
investor meetings at all of the conferences. If you plan to attend
at least one of the conferences and are interested in meeting with
management, please contact your Cowen, Raymond James or H.C.
Wainwright representative.
A live webcast of the fireside chats during the Cowen 41st
Annual Health Care Conference and the Raymond James 42nd Annual
Institutional Investors Conference, along with a replay of the
pre-recorded presentation during the H.C. Wainwright Global Life
Sciences Conference, can be accessed by visiting the Investors
section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA, is FDA-approved for the treatment of ocular inflammation
and pain following ophthalmic surgery. Ocular Therapeutix has also
submitted a Supplemental NDA for DEXTENZA to include the treatment
of ocular itching associated with allergic conjunctivitis as an
additional approved indication. Ocular Therapeutix’s earlier stage
development assets currently in Phase 1 clinical trials include
OTX-TKI (axitinib intravitreal implant) for the treatment of wet
AMD and other retinal diseases and OTX-TIC (travoprost intracameral
implant) for the reduction of intraocular pressure in patients with
primary open-angle glaucoma or ocular hypertension. Ocular
Therapeutix is currently evaluating OTX-CSI (cyclosporine
intracanalicular insert) for the treatment of dry eye disease in a
Phase 2 clinical trial. Also, Ocular Therapeutix has recently filed
a Phase 2-enabling investigational new drug application for OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease. Also, in
collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal
injection) is in pre-clinical development as an extended-delivery
formulation of aflibercept for the treatment of retinal diseases.
Ocular Therapeutix's first product, ReSure® Sealant is an FDA
approved device to prevent wound leaks in corneal incisions
following cataract surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210224005326/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com
or
Westwicke, an ICR Company Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2024 to May 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From May 2023 to May 2024